A Novel FMRI Biomarker of Asymptomatic HIV-Associated Neurocognitive Disorders

无症状 HIV 相关神经认知障碍的新型 FMRI 生物标志物

基本信息

  • 批准号:
    9265967
  • 负责人:
  • 金额:
    $ 43.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-01 至 2020-04-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Despite the widespread use of combination antiretroviral therapy (cART), approximately half of individuals with HIV-infection are affected by HIV-associated neurocognitive disorders (HAND). Individuals with even the mildest form of HAND, asymptomatic neurocognitive impairment (ANI), are at increased risk of antiretroviral non-adherence, virologic failure, unemployment and mortality. There has been increasing pressure to identify neural targets for interventional behavioral and medical therapies, especially among persons at risk of progression to symptomatic HAND. Early interventions (prior to potentially additive neural damage) are likely to be more effective and have a better chance to preserve and improve cognitive function. Despite this significant public health need, finding a biomarker that can accurately assess current neurocognitive disease stage and reliably predict future HAND progression remains a major challenge. Here we hypothesize that, in HIV+ individuals without symptomatic HAND, subtle neuronal dysfunction due to synaptodendritic injury, not currently assessed clinically, is present and can be detected and quantitated using the novel functional magnetic resonance imaging (fMRI) techniques we recently developed and validated. In this 5-year cross- sectional and longitudinal study, we aim to further validate and improve these fMRI biomarkers (based on two novel techniques) with a larger sample size, both cross-sectionally and longitudinally (primary goal). We will study a total of 160 subjects over five years. These will include 100 neurocognitively normal/ANI HIV-positive, virally suppressed adults on cART, and 60 matched HIV negative controls. HIV+ individuals will have a 24- month follow-up visit. Based on a recent study (Grant et al., Neurology, 2014), we expect about 20 HIV+ participants will transition from neurocognitively normal or ANI to symptomatic HAND over the 2-year period. This longitudinal data will provide us an opportunity to follow the trajectories of transition with novel fMRI techniques and to identify potential markers of risk for progression to symptomatic HAND (secondary goal). This project has three specific aims: Aim 1: To test the hypothesis that HIV impairs neurocognitive function by decreasing neural specificity in key brain regions and to identify brain regions that are most vulnerable to HIV- disease (i.e., those with the greatest reductions in neural specificity). Aim 2: To test the hypothesis that HAND leads to accelerated/premature aging of the brain, by calculating a functional age of the HIV-infected brain with multivariate pattern analysis (MVPA) of fMRI activations relative to HIV-uninfected controls, and to quantify accelerated aging in HIV at the whole-brain level as a single diagnostic number, Hage (Hage = functional age minus chronological age) that can be linked to HAND progression and future risk, with a strong potential to serve as a biomarker of HAND in clinical settings. Aim 3: To evaluate the neural bases of reduced executive function due to HIV infection, one of the most common and key deficits that underlies a broad range of neurocognitive impairments associated with HAND. The success of this proposed project is expected to provide clinicians and researchers with a validated set of tools/biomarkers to quantitatively assess early pathological changes and to predict future HAND progression, with a strong potential to guide and evaluate interventions that might slow down or prevent progression to symptomatic HAND.
 描述(由申请人提供): 尽管广泛使用联合抗逆转录病毒疗法(cART),但大约一半的HIV感染者受到HIV相关神经认知障碍(HAND)的影响。即使是最轻微的HAND,即无症状神经认知障碍(ANI),也会增加抗逆转录病毒治疗不依从性,病毒学失败,失业和死亡的风险。识别神经靶点进行干预行为和药物治疗的压力越来越大,特别是在有进展为症状性HAND风险的人群中。早期干预(在潜在的附加神经损伤之前)可能更有效,并且有更好的机会保持和改善认知功能。尽管有这一重大的公共卫生需求,但找到一种可以准确评估当前神经认知疾病阶段并可靠预测未来HAND进展的生物标志物仍然是一个重大挑战。在这里,我们假设,在没有症状的手,微妙的神经元功能障碍,由于突触树突损伤,目前尚未进行临床评估,是存在的,可以检测和定量使用新的功能磁共振成像(fMRI)技术,我们最近开发和验证。在这项为期5年的横向和纵向研究中,我们的目标是进一步验证和改善这些fMRI生物标志物(基于两种新技术),样本量更大,横向和纵向(主要目标)。我们将在五年内研究总共160个主题。这些将包括100名接受cART治疗的神经认知正常/ANI HIV阳性、病毒抑制的成年人和60名匹配的HIV阴性对照。HIV阳性者将接受24个月的随访。根据最近的一项研究(Grant等人,Neurology,2014),我们预计约20名HIV+参与者将在2年内从神经认知正常或ANI转变为症状性HAND。这种纵向数据将为我们提供一个机会,用新的功能磁共振成像技术跟踪过渡的轨迹,并确定进展为症状性手(次要目标)的潜在风险标志物。该项目有三个具体目标:目标1:测试HIV通过降低关键脑区的神经特异性来损害神经认知功能的假设,并确定最易受HIV疾病影响的脑区(即,神经特异性降低最大的那些)。目标二:为了检验HAND导致大脑加速/过早老化的假设,通过使用相对于HIV未感染对照的fMRI激活的多变量模式分析(MVPA)计算HIV感染大脑的功能年龄,并在全脑水平上将HIV的加速老化量化为单个诊断数字,Hage(Hage =功能年龄减去实际年龄)可能与HAND进展和未来风险相关,具有很强的潜力作为临床环境中HAND的生物标志物。目标三:评估HIV感染导致执行功能降低的神经基础,这是一种最常见和关键的缺陷,是与HAND相关的广泛神经认知障碍的基础。该拟议项目的成功有望为临床医生和研究人员提供一套经验证的工具/生物标志物,以定量评估早期病理变化并预测未来的HAND进展,具有指导和评估可能减缓或预防症状性HAND进展的干预措施的强大潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xiong Jiang其他文献

Xiong Jiang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xiong Jiang', 18)}}的其他基金

An advanced functional MRI study of frontostriatal injury in adults with HIV
成人 HIV 感染者额纹状体损伤的高级功能 MRI 研究
  • 批准号:
    10671627
  • 财政年份:
    2022
  • 资助金额:
    $ 43.61万
  • 项目类别:
An advanced functional MRI study of frontostriatal injury in adults with HIV
成人 HIV 感染者额纹状体损伤的高级功能 MRI 研究
  • 批准号:
    10403223
  • 财政年份:
    2022
  • 资助金额:
    $ 43.61万
  • 项目类别:
An advanced functional MRI study of frontostriatal injury in adults with HIV
成人 HIV 感染者额纹状体损伤的高级功能 MRI 研究
  • 批准号:
    10450246
  • 财政年份:
    2021
  • 资助金额:
    $ 43.61万
  • 项目类别:
A Novel FMRI Biomarker of Asymptomatic HIV-Associated Neurocognitive Disorders
无症状 HIV 相关神经认知障碍的新型 FMRI 生物标志物
  • 批准号:
    9098851
  • 财政年份:
    2015
  • 资助金额:
    $ 43.61万
  • 项目类别:
A Novel FMRI Biomarker of Asymptomatic HIV-Associated Neurocognitive Disorders
无症状 HIV 相关神经认知障碍的新型 FMRI 生物标志物
  • 批准号:
    8993111
  • 财政年份:
    2015
  • 资助金额:
    $ 43.61万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.61万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了